+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID04510636

Evaluating Safety and Effectiveness of Pembrolizumab Combined With Bendamustine for Adults With Relapsed or Refractory Classical Hodgkin Lymphoma

Led by University Health Network, Toronto · Updated on 2026-06-23

40

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of combining pembrolizumab and bendamustine in adults with relapsed or refractory classical Hodgkin lymphoma. The study focuses on patients whose cancer has returned or stopped responding to previous treatments, addressing the limited options available after standard therapies fail or are not tolerated. Participants will receive pembrolizumab and bendamustine administered in cycles lasting three weeks each. Pembrolizumab is given as a 200 mg infusion over 30 minutes once every cycle for up to 35 cycles approximately 24 months. Bendamustine is given at 90 mgm2 over 60 minutes on days 1 and 2 of each cycle for up to 6 cycles. The combination aims to improve response duration while limiting side effects by using drugs with non-overlapping toxicities. During the study, participants will undergo assessments including CT and PET scans to measure tumor response, as well as regular laboratory tests to monitor organ and bone marrow function. Researchers will evaluate response rates, survival, progression-free survival, and safety over a five-year period. Participants will be monitored throughout treatment and follow-up to assess the overall impact of the treatment combination.

CONDITIONS

Brief Title

Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma

Research Team

J

John Kuruvilla, M.D.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here